MX2019009126A - Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh). - Google Patents

Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).

Info

Publication number
MX2019009126A
MX2019009126A MX2019009126A MX2019009126A MX2019009126A MX 2019009126 A MX2019009126 A MX 2019009126A MX 2019009126 A MX2019009126 A MX 2019009126A MX 2019009126 A MX2019009126 A MX 2019009126A MX 2019009126 A MX2019009126 A MX 2019009126A
Authority
MX
Mexico
Prior art keywords
gnrh
antagonists
methods
compositions
long term
Prior art date
Application number
MX2019009126A
Other languages
English (en)
Inventor
Ravi Kacker
Mitchell S Steiner
Original Assignee
Veru Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veru Inc filed Critical Veru Inc
Publication of MX2019009126A publication Critical patent/MX2019009126A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Abstract

La invención proporciona composiciones y métodos para la liberación prolongada de antagonistas de la hormona liberadora de gonadotropina (GnRH), y usos de estos. Específicamente, la invención proporciona composiciones poliméricas y métodos para la liberación controlada de antagonistas de GnRH.
MX2019009126A 2017-01-31 2018-01-31 Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh). MX2019009126A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452788P 2017-01-31 2017-01-31
PCT/US2018/016241 WO2018144603A1 (en) 2017-01-31 2018-01-31 COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS

Publications (1)

Publication Number Publication Date
MX2019009126A true MX2019009126A (es) 2020-01-20

Family

ID=62976965

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009126A MX2019009126A (es) 2017-01-31 2018-01-31 Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
MX2022003967A MX2022003967A (es) 2017-01-31 2019-07-31 Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003967A MX2022003967A (es) 2017-01-31 2019-07-31 Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).

Country Status (18)

Country Link
US (2) US20180214507A1 (es)
EP (2) EP4011386A1 (es)
JP (1) JP7074963B2 (es)
KR (1) KR20190110567A (es)
CN (1) CN110234336A (es)
AU (1) AU2018217064A1 (es)
CA (1) CA3052157A1 (es)
DK (1) DK3576771T3 (es)
ES (1) ES2914314T3 (es)
HR (1) HRP20220438T1 (es)
HU (1) HUE058207T2 (es)
IL (1) IL268376A (es)
LT (1) LT3576771T (es)
MX (2) MX2019009126A (es)
PL (1) PL3576771T3 (es)
PT (1) PT3576771T (es)
UA (1) UA127018C2 (es)
WO (1) WO2018144603A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7069155B2 (ja) 2017-06-29 2022-05-17 株式会社ソニー・インタラクティブエンタテインメント ロボットの制御装置、制御方法および制御プログラム
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
JP2022504427A (ja) * 2018-10-02 2022-01-13 インノコア テクノロジーズ ホールディング ビー．ブイ． ヒト絨毛性ゴナドトロピン（ｈＣＧ）の徐放配合物
CN110681323B (zh) * 2019-08-26 2021-12-21 上海摩漾生物科技有限公司 具有微拓扑结构的高尔夫球型可降解微球及其制备方法
WO2021237039A1 (en) * 2020-05-21 2021-11-25 Veru Inc. Compositions and methods for long term release of gonadotropin-releasing hormone (gnrh) antagonists
CN111728957B (zh) * 2020-07-06 2022-04-19 济南大学 一种托特罗定长效缓释微球及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US6805879B2 (en) 2000-06-23 2004-10-19 Biopharm Solutions Inc. Stable polymer aqueous/aqueous emulsion system and uses thereof
AU2001295359A1 (en) 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
KR100435921B1 (ko) 2000-12-29 2004-06-12 주식회사 태평양 동수역학적 이중 안정화에 의한 안정한 수-유-수 다중에멀젼 시스템 및 이의 제조방법
SI21222A (sl) 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
EP1382628A1 (en) * 2002-07-16 2004-01-21 Polyganics B.V. Biodegradable phase separated segmented/block co-polyesters
ME00509B (me) 2002-09-27 2011-10-10 Zentaris Gmbh Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje
ES2600554T3 (es) * 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
JP2008525436A (ja) * 2004-12-23 2008-07-17 デュレクト コーポレーション 放出制御組成物
SI1939204T1 (sl) 2005-10-19 2013-05-31 Kissei Pharmaceutical Co., Ltd. Kondenziran heterociklični derivat, medicinski sestavek, ki ta derivat vsebuje, in njegova medicinska uporaba
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
ES2569556T3 (es) * 2008-06-03 2016-05-11 Indivior Uk Limited Complejo de inclusión de hidrogel deshidratado de un agente bioactivo con sistema fluido de administración de medicamento
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
EP2246063A1 (en) * 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
TR200907227A2 (tr) 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
US8975270B2 (en) * 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
DK2590629T3 (en) 2010-07-09 2015-01-12 Innocore Technologies B V Biodegradable PHASE SEPARATED, SEGMENTED MULTI block copolymers AND RELEASE OF BIOLOGICAL ACTIVE POLYPEPTIDES
CN102145160A (zh) * 2011-03-07 2011-08-10 深圳市健元医药科技有限公司 一种lhrh拮抗剂注射用的缓释植入制剂
US20140213459A1 (en) 2011-05-27 2014-07-31 Roland Beckmann Antibodies with improved folding stability
MY169349A (en) 2011-07-22 2019-03-21 Innocore Tech B V Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds
CN102488619B (zh) 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
EP3122331A1 (en) 2014-03-27 2017-02-01 Novartis AG Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
US20170290846A1 (en) * 2014-09-30 2017-10-12 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery
US20160106804A1 (en) 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
ES2914314T3 (es) 2022-06-09
AU2018217064A1 (en) 2019-08-08
KR20190110567A (ko) 2019-09-30
US20180250354A1 (en) 2018-09-06
EP4011386A1 (en) 2022-06-15
CN110234336A (zh) 2019-09-13
RU2019123951A3 (es) 2021-08-02
UA127018C2 (uk) 2023-03-15
JP7074963B2 (ja) 2022-05-25
EP3576771A1 (en) 2019-12-11
RU2019123951A (ru) 2021-02-01
IL268376A (en) 2019-09-26
EP3576771B1 (en) 2022-03-09
HRP20220438T1 (hr) 2022-06-10
PT3576771T (pt) 2022-05-30
WO2018144603A1 (en) 2018-08-09
US20180214507A1 (en) 2018-08-02
LT3576771T (lt) 2022-04-11
DK3576771T3 (da) 2022-05-30
HUE058207T2 (hu) 2022-07-28
JP2020506232A (ja) 2020-02-27
PL3576771T3 (pl) 2022-08-16
MX2022003967A (es) 2022-04-25
EP3576771A4 (en) 2020-11-04
CA3052157A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2022003967A (es) Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2022002026A (es) Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos.
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MA39999A (fr) Agonistes du récepteur de l'apeline (apj) et leurs utilisations
MY191581A (en) Anti-pd-1 antibodies
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MX2019006539A (es) Sistemas y metodos para la extraccion de productos naturales.
MX2019001313A (es) Composiciones farmaceuticas.
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12018502714A1 (en) Nicotine particles and compositions
MX2018015247A (es) Heterociclos de biarilmetilo.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EP3957723A3 (en) Engineered ligase variants
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.